drugset / Trial / NCT05306444
CLN-418 Study on Subjects With Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
Study to evaluate the safety and tolerability of the study drug CLN-418, to determine the maximum tolerated dose and/or recommended Phase 2 study dose of CLN-418.
Timeline
- Start
- 2022-05-12
- Primary completion
- 2024-08-28
- Completion
- 2024-09-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CLN-418 | Unknown | — | Intravenous |